HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.1, reflecting a period of significant pressure for the biopharmaceutical company. With a market ...

NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...

StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report ... rating and a $35.00 price objective for the company. B. Riley reduced their price objective on shares ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP advanced 2.91% to $9.90 Thursday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index ...

Corbus Pharmaceuticals Holdings Inc. closed 84.18% below its 52-week high of $61.90, which the company achieved on July 31st.